Identification of DPYD variants and estimation of uracil and dihydrouracil in a healthy Indian population.
Per Med
; 20(1): 39-53, 2023 01.
Article
en En
| MEDLINE
| ID: mdl-36416570
Background: 5-fluorouracil (5-FU) is a medicine used in cancer treatment. It is eliminated from body by the enzyme DPD. Identifying deficiency in DPD before initiating 5-FU can save patients from oral, intestinal, and bone marrow toxic effects. Methods: The uracil and dihydrouracil (DHU, produced by DPD enzyme action) levels were measured and DPD gene (for identifying defects) was sequenced in 100 healthy adults. Results: Participants with DPD gene sequence that is known to be defective had higher plasma uracil levels and a low DHU-to-uracil ratio compared with those who did not have a defective gene. Conclusion: Measuring plasma uracil and DHU-to-uracil ratio can help identify people with defective DPD genes.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Uracilo
/
Dihidrouracilo Deshidrogenasa (NADP)
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Revista:
Per Med
Año:
2023
Tipo del documento:
Article
País de afiliación:
India